Adrenomedullin (AM) is a multifunctional peptide involved in roles as varied as blood pressure regulation, growth, neurotransmission, and inflammation control, among others. We previously identified complement factor H as a serum binding protein for AM and showed that factor H regulates AM functions and vice versa. 
have been shown to increase in many disease states such as heart failure, hypertension, and septic shock (3) . The standard method for measuring AM in plasma requires an extraction step with Sep-Pak C-18 cartridges prior to the quantitation of AM by RIA (4) . Without this step, the displacement of 125 I-AM from the primary antibody by increasing concentrations of plasma is not parallel to the displacement slope of synthetic AM in the assay standard curve. Also, the recovery of 125 I-AM is usually higher than the total binding (B0) in the assay. In Sephadex G-50 chromatography, the elution pattern of 125 
Introduction
Human adrenomedullin (AM) is a 52-amino acid peptide originally isolated from a human pheochromocytoma and identified as a molecule capable of elevating rat platelet cyclic adenosin monophosphate (cAMP) and reducing blood pressure (1) . AM belongs to the calcitonin gene-related peptide (CGRP) family of peptides and is involved in a variety of functional roles that include, among others, blood pressure regulation, bronchodilatation, renal function, hormone secretion, cell growth, differentiation, neurotransmission, and modulation of the immune response. For a recent review see Ref.
2.
AM has been found by radioimmunoassay (RIA) in many bodily fluids including plasma, cerebrospinal fluid, sweat, amniotic fluid, urine, and milk (2) . In addition, AM levels and aid to its stability (6) .
Based on these observations, we developed a radioligand blotting technique for AM and described the existence of an AM-binding protein in the plasma of several species (5) . All species analyzed (chick, calf, dog, goat, guinea pig, human, mouse, pig, rabbit, and sheep) contained an AM-binding protein with an apparent molecular weight of 120 kDa under reducing conditions. Interestingly, the plasma of ruminant species (calf, goat, and sheep) contained an additional band of 140 kDa. When comparing the contents of AM-binding protein between normal calves and animals subjected to a parasitic infection, the latter showed a significant reduction in the levels of the circulating protein, indicating that the AM-binding protein may be regulated in disease states in addition to AM. This suggests that the levels of both proteins should be measured in order to correctly interpret the meaning of AM changes in patients' plasma (5) .
To further characterize the biochemical nature of this binding protein, we used a non-radioactive ligand blotting assay in combination with high performance liquid chromatography (HPLC) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) techniques to purify this protein to homogeneity. Subsequent analysis by amino acid composition, end-terminal sequencing, matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI/MS), and tandem mass spectrometry (MS/MS) identified this binding protein as human complement factor H (7). Factor H is a key regulatory component in the alternative pathway of the complement cascade. Factor H binds to C3b, displacing Bb from the C3 convertase and thereby inactivating its activity. Factor H is also a necessary cofactor for the inactivation of C3b by factor I. In summary, factor H inhibits the alternative pathway of the complement (8) . We have shown that factor H is able to increase the activities of AM in several models, including cAMP induction, tumor cell growth (7) , and repression of insulin release (9) . Conversely, AM is also able to increase factor H-mediated degradation of C3b (7) .
Factor H is a 150 kDa glycoprotein present in human plasma at a concentration of 500 µg/ml (10) . Factor H is composed of 20 repetitive domains termed short consensus repeats (SCR), each approximately 60 amino acids in length (11) . This molecule belongs to a protein family that contains other members, such as factor H-like protein 1 (FHL-1), factor H related protein 1 (FHR-1), FHR-2, FHR-3, FHR-4, and FHR-5 (12, 13) . FHL-1 is a 42 kDa protein generated by alternative splicing from the factor H gene, and its sequence is identical to the seven N-terminal domains of factor H, with four unique amino acids at the carboxy terminus. FHL-1 regulates the complement cascade in a manner comparable to factor H. The FHRs are composed of 4, 5, or 8 SCR and their functions remain unclear (12, 13) .
To better understand the interactions between AM and factor H, we performed a structure-function analysis to identify the topography of the AM-binding sites within this complement regulatory protein.
Methods

Chemicals
Synthetic human AM was obtained from Peninsula Laboratories (Belmont, USA). Purified human factor H was purchased from Sigma (St. Louis, USA). Recombinant fragments of factor H have been described previously (14) . Antibodies against complement factor H include two monoclonals (OX23, OX24) from Serotec (Oxford, UK) and a goat polyclonal from Quidel (San Diego, USA). Mouse and goat isotypic control IgGs were obtained from Sigma.
Labeling of Adrenomedullin
Non-radioactive labeling was accomplished by conjugation of synthetic human AM with fluorescein-5-EX succinimidyl ester (Molecular Probes, Eugene, USA) as previously described (7) . To remove the unbound fluorescein, the labeled AM was mixed with an equal volume of 0.1% alkali-treated casein (ATC) in Tris-buffered saline (TBS), pH 7.4, and extracted using reverse phase Sep-Pak C-18 cartridges (Waters, Milford, USA) with 80% acidic-isopropanol as the elution buffer. Extract was lyophilized and reconstituted in 1 ml TBS containing 0.1% ATC, 0.1% Tween-20, and 0.05% Triton X-100, pH 7.4. Fluorescein-labeled AM was stored at 4 ºC for as long as 3 months without significant loss of activity.
Binding Assays
A 96-well PVC plate was coated with 5 ng/well of purified human factor H in TBS (1 h at room temperature). Afterwards, the plate was blocked with TBS/0.1% ATC/0.1% Tween-20 for 2 h at room temperature, and fluorescein-labeled AM (50 nmol/l) was added (overnight at 4 ºC). The assay was developed with an anti-fluorescein polyclonal antibody (1:1,000; Molecular Probes), followed by 125 I-Protein A (Amersham Pharmacia, Piscataway, USA). The radioactivity was determined using a gamma counter. For competition of the binding, the recombinant proteins were incubated with the fluorescein-labeled AM (50 nmol/l) for 6 h at 4 ºC, and then the mixture was added to the plate.
Results
First, to characterize our binding assay, we competed the binding of fluorescein-labeled AM to solid-phase factor H with 1 µmol/l purified factor H, obtaining a 91% reduction in the amount of radioactivity bound to the plate. In contrast, when 25 µmol/l albumin was used as a negative control, no difference with the un-competed control was observed (Fig.  1) . We then investigated whether C3b, which is known to bind factor H in three different regions (15) (16) (17) , was able to compete for the AM-binding sites. Figure 1 shows that increasing concentrations of C3b of up to 1 mmol/l did not have any effect on the binding of AM to solid-phase factor H. Addition of either the monoclonal or polyclonal antibodies against factor H completely blocked the binding, whereas application of the isotypic controls did not (results not shown).
To localize the potential binding sites for AM, increasing concentrations of factor H (as a positive control), FHL-1 (which is almost identical to SCR 1-7), and SCR 8-20 were added to the assay (Fig. 2) . Both factor H and SCR 8-20 decreased AM binding with almost overlapping kinetics, indicating they have a similar affinity for AM. This is not the case for FHL-1, which had at least 20-fold less affinity than the other molecules (Fig. 2) . Since FHL-1 and SCR 8-20 cover the complete factor H molecule, we could conclude that AM binds to the middle and/or carboxy-terminal part of factor H but neither to its amino end, nor to FHL-1.
To further characterize these binding sites, we competed AM binding with smaller fragments of the 8-20 region of factor H (Fig. 3) . One of these fragments, SCR 11-15, did not have any significant binding affinity for AM. On the other hand, SCR 8-11 had a moderate affinity, whereas SCR 15-20 showed a high affinity comparable to that exhibited by complete factor H or by SCR 8-20 (Fig. 3) .
Finally, we tried to more precisely map the high affinity binding site by using smaller fragments of SCR 15-20 (Fig.  4) . For both fragments, the affinity for AM was much lower than that for SCR 15-20, indicating that either the bridge between SCR 18 and 19 is required for AM binding or that the small recombinant proteins lost some important spatial conformation needed for recognizing AM.
Discussion
We have mapped the binding of AM to two regions of the factor H molecule (Fig. 5) . We have found a high affinity binding site within the SCR 15-20 and a lower affinity site in SCR 8-11. In addition, smaller fragments of SCR 15-20 showed low interaction with AM. The existence of high and low affinity binding sites for AM was predicted in a previous article in which dissociation of the factor H-AM interaction was studied by incubation with sodium thiocyanate for different periods of time (7).
Structure-function analysis of factor H has demonstrated that the domains required for complement regulation are lo- 
Fig. 4. Competition with fragments that span short consensus repeats (SCR) 15-20: 15-18 and 19-20. Bars represent the mean SD of triplicate determinations from two independent experiments.
Fig. 2. Characterization of the binding site. AM binding was competed with different concentrations of factor H (FH), factor H-like protein-1 (FHL-1), and short consensus repeats (SCR) 8-20. Points represent the mean SD of three independent determinations from a representative experiment. The experiment was repeated three times with similar results.
cated within the four N-terminal SCRs. Three C3b-binding sites have been identified in factor H (15, 16) , and each of the three interacts with a distinct site on C3b (17) . Three binding sites for polyanions have been identified as well. Two of these sites have been localized to SCR 7 and 20 (18, 19) , while the other is in or near SCR 13 (20) . SCR 8-11 represents a recently recognized interaction domain of factor H. In addition to AM, this domain also binds the acute phase protein C reactive protein (21) and the streptococcal surface protein β (22); thus a rather active site is present in the middle region of factor H. In addition, the C-terminal binding site seems to be very active for binding interactions. For instance, one of the binding sites for C3b occurs in SCR 19-20 (15, 16) and one of the polyanion binding sites is located in SCR 20 (19) . This is also the more active site for AM binding, although it seems that a complex three-dimensional interaction is needed to accomplish it, since smaller fragments of the region failed to compete for AM binding.
It is intriguing that AM is able to discriminate between factor H and FHL-1 by binding with high affinity to the first molecule and with very low affinity to the second. Both proteins have been shown to regulate the alternative pathway of the complement cascade (23) . AM increases factor H cofactor activity in the cleavage of C3b (7), and therefore, in view of the present data, we could predict a difference in the behavior of factor H and FHL-1 in regulating complement fixation in the presence of AM.
The binding between AM and factor H has important physiological implications. The presence of a binding protein can modify the concentration and availability of a factor in biological fluids. The binding protein can alter the halflife of the factor, and may either stimulate or inhibit its activity. In the case of AM, its binding to factor H can result in contradictory effects. For instance, factor H can block the non-receptor mediated antimicrobial activity of AM on Escherichia coli, but results in an increase of AM activity on receptor-mediated events such as elevation of intracellular cAMP in Rat2 fibroblasts, tumor cell growth, and inhibition of insulin release from pancreatic islets (7, 9) . At this time, we can only speculate as to the details of the mechanism by which factor H exerts its influence on AM (and vice versa). One possible explanation for the increase in AM activity involves the presence of receptors for factor H in the cell membrane (24, 25) . Factor H may bind to its specific receptors in the cell membrane, thereby carrying AM in close proximity to its own receptor. This mechanism would increase AM efficiency without affecting the kinetics of receptor binding, which do not change (7). In addition, factor H may protect AM from degradation from proteases present in the cell membrane, thus prolonging its half-life.
Another interesting corollary of the interaction between AM and factor H is the influence that AM exerts in regulating the complement cascade through its binding to factor H (7). This is yet another level at which AM contributes to modulating the immune system (26) .
Solid phase competition experiments such as that shown in Fig. 2 suggest an EC50 value in the range of 100 to 200 nmol/l for the interaction between AM and factor H. This moderate affinity is expected in the interaction between a peptide and its chaperon protein and indicates that in the presence of the high affinity AM receptor (KD between 1 and 10 nmol/l), the equilibrium would be tilted towards the receptor and AM would be efficiently delivered near the receptor site. Although these values can not be extrapolated to the actual values in biological fluids, the high concentration of factor H in the serum and its affinity for AM challenge our previous concept of AM as a molecule circulating at only femtomolar concentrations. Even though the specific levels of total circulating AM are unknown at this time, we expect them to be much higher than initially reported. The fact that the binding protein may vary during disease states (5) indicates that we should re-evaluate the variations of total AM levels in clinical disorders (3), taking into consideration the contributions of factor H.
In conclusion, the binding of AM to factor H is restricted to two regions of the complement component, one having high affinity and localized towards the carboxy terminus, and a second low-affinity site in the middle of the factor H backbone. A clearer understanding of the binding between these two molecules may help to clarify their contribution to physiological and pathophysiological conditions.
